Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 18/20 | 0.80 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.75 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6872045 | 1.00 | ADRB3 (0.80) | ADRB3ADRB2ADRB1MEN1CYP1A2 | |
| SCHEMBL6872042 | 1.00 | ADRB3 (0.80) | ADRB3ADRB2ADRB1MEN1CYP1A2 | |
| SCHEMBL6872047 | 1.00 | ADRB3 (0.80) | ADRB3ADRB2ADRB1MEN1CYP1A2 | |
| SCHEMBL6870939 | 0.94 | ADRB3 (0.79) | ADRB3ADRB2ADRB1MEN1CYP1A2 | |
| SCHEMBL6870935 | 0.94 | ADRB3 (0.79) | ADRB3ADRB2ADRB1MEN1CYP1A2 | |
| SCHEMBL6870932 | 0.94 | ADRB3 (0.79) | ADRB3ADRB2ADRB1MEN1CYP1A2 | |
| SCHEMBL6872440 | 0.90 | ADRB3 (0.74) | ADRB3ADRB2ADRB1MEN1CYP1A2 | |
| SCHEMBL6872451 | 0.90 | ADRB3 (0.74) | ADRB3ADRB2ADRB1MEN1CYP1A2 | |
| SCHEMBL6865432 | 0.90 | ADRB3 (0.76) | ADRB3ADRB2ADRB1MEN1CYP1A2 | |
| SCHEMBL6865430 | 0.90 | ADRB3 (0.76) | ADRB3ADRB2ADRB1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6583140-B2 | Useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders | WYETH | 2003-06-24 | — | — | US | disclosed |